Literature DB >> 15030652

Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,.

M Concepción Bratti1, Ana C Rodríguez, Mark Schiffman, Allan Hildesheim, Jorge Morales, Mario Alfaro, Diego Guillén, Martha Hutchinson, Mark E Sherman, Claire Eklund, John Schussler, Julie Buckland, Lidia A Morera, Fernando Cárdenas, Manuel Barrantes, Elmer Pérez, Thomas J Cox, Robert D Burk, Rolando Herrero.   

Abstract

OBJECTIVE: The Guanacaste study ("Guanacaste Project," or GP), was designed to investigate the role of human papillomavirus (HPV) infection and its cofactors in the development of cervical neoplasia and to evaluate new cervical cancer screening technologies. The follow-up phase of the GP was designed to study why a small proportion of women infected with HPV develop cervical intraepithelial neoplasia grade 2 (CIN 2), CIN 3, or cancer (these three together are globally referred to as > or = CIN 2, that is, CIN 2 or worse). The purpose of this article is to describe this prospective study in detail and to present the preliminary findings regarding the incidence of cervical neoplasia.
METHODS: A cohort of 10 049 randomly selected women from 18 to 97 years old from Guanacaste, a province in northwestern Costa Rica, was intensively screened in 1993-1994 and then followed up for seven years after being enrolled. A questionnaire for demographic and risk factors was administered, and a pelvic examination was performed on sexually active women at each follow-up visit in order to obtain samples for screening tests and for research purposes. The final diagnosis given at the end of the enrollment phase categorized women into several groups according to the perceived risk of their developing either high-grade precursors of cancer or cancer. These groups were followed up at different intervals according to the risk of developing > or = CIN 2. The most active follow-up (every 6-12 months) was concentrated on the women most likely to develop >or = CIN 2, based on cytology (n = 492). The remainder of the cohort was followed either annually (n = 2 574) or after five to seven years of passive follow-up (n = 3 926). All women with possibly severe lesions detected by any technique were referred to colposcopy for further evaluation and treatment, and they were also censored from the study. Lesions >or = CIN 2 served as both the censoring outcome and our surrogate for cancer risk.
RESULTS: Participation during follow-up was high (near 90%). Suspected > or = CIN 2 by any screening technique censored 4.6% of women. Most of the women censored because of suspected > or = CIN 2 came from the large group perceived at entry as being at low risk of developing > or = CIN 2, but the greatest rates of progression to > or = CIN 2 were observed among women perceived at entry to be at highest risk of > or = CIN 2, based on their cytology, virology, or sexual behavior.
CONCLUSIONS: The GP is the largest population-based longitudinal cohort for the study of HPV and cervical neoplasia in the world, and its results will hopefully let us soon plan future worldwide prevention strategies. Research projects such as this one require the long-term commitment of a large multidisciplinary team and ample financial resources. The intensive effort and expertise applied in all aspects of this study were key factors in its success as a model of cooperative, interdisciplinary cancer research in Latin America. Quality control played an important role at all times during the study and made it possible to adapt new diagnostic and screening technology to Guanacaste. The systematic follow-up of a population-based group of close to 10 000 women in Guanacaste should permit careful, time-dependent evaluation of factors postulated to be linked to the development of cervical cancer as well as the evaluation of clinical markers of disease progression. The study results that have already been published have validated sensitive screening techniques and have also promoted the use of more affordable screening techniques in resource-poor, developing countries. The GP has also contributed to building knowledge for the search for vaccines against HPV as part of the effort to develop an effective tool to reduce the incidence and mortality of cervical cancer worldwide.

Entities:  

Mesh:

Year:  2004        PMID: 15030652     DOI: 10.1590/s1020-49892004000200002

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


  43 in total

1.  Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting.

Authors:  Sarah Coseo Markt; Ana C Rodriguez; Robert D Burk; Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Martha Hutchinson; Mark Schiffman
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

2.  Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection.

Authors:  Troy J Kemp; Allan Hildesheim; Alfonso García-Piñeres; Marcus C Williams; Gene M Shearer; Ana Cecilia Rodriguez; Mark Schiffman; Robert Burk; Enrique Freer; Jose Bonilla; Rolando Herrero; Ligia A Pinto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

3.  Human papillomavirus genotyping after denaturation of specimens for Hybrid Capture 2 testing: feasibility study for the HPV persistence and progression cohort.

Authors:  Brandon J LaMere; Janet Kornegay; Barbara Fetterman; Mark Sadorra; Jen Shieh; Philip E Castle
Journal:  J Virol Methods       Date:  2007-07-27       Impact factor: 2.014

4.  Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.

Authors:  Mahboobeh Safaeian; Koen Quint; Mark Schiffman; Ana Cecilia Rodriguez; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Raphael P Viscidi; Wim Quint; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2010-11-23       Impact factor: 13.506

Review 5.  [Prophylactic and therapeutic HPV immunization].

Authors:  M Müller; L Gissmann
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

6.  An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening.

Authors:  Liming Hu; David Bell; Sameer Antani; Zhiyun Xue; Kai Yu; Matthew P Horning; Noni Gachuhi; Benjamin Wilson; Mayoore S Jaiswal; Brian Befano; L Rodney Long; Rolando Herrero; Mark H Einstein; Robert D Burk; Maria Demarco; Julia C Gage; Ana Cecilia Rodriguez; Nicolas Wentzensen; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

7.  Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.

Authors:  Ana Cecilia Rodríguez; Alfonso J García-Piñeres; Allan Hildesheim; Rolando Herrero; Matthew Trivett; Marcus Williams; Ivannia Atmella; Margarita Ramírez; Maricela Villegas; Mark Schiffman; Robert Burk; Enrique Freer; José Bonilla; Concepción Bratti; Ligia A Pinto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

8.  Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer.

Authors:  Philip E Castle; Ana C Rodríguez; Robert D Burk; Rolando Herrero; Allan Hildesheim; Diane Solomon; Mark E Sherman; Jose Jeronimo; Mario Alfaro; Jorge Morales; Diego Guillén; Martha L Hutchinson; Sholom Wacholder; Mark Schiffman
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

9.  HPV16 CpG methyl-haplotypes are associated with cervix precancer and cancer in the Guanacaste natural history study.

Authors:  Marina Frimer; Chang Sun; Thomas McAndrew; Benjamin Smith; Ariana Harari; Zigui Chen; Lisa Mirabello; Nicolas Wentzensen; Gary L Goldberg; Ana C Rodriguez; Mark Schiffman; Robert D Burk
Journal:  Gynecol Oncol       Date:  2015-05-19       Impact factor: 5.482

10.  Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia.

Authors:  Lisa Mirabello; Mark Schiffman; Arpita Ghosh; Ana C Rodriguez; Natasa Vasiljevic; Nicolas Wentzensen; Rolando Herrero; Allan Hildesheim; Sholom Wacholder; Dorota Scibior-Bentkowska; Robert D Burk; Attila T Lorincz
Journal:  Int J Cancer       Date:  2012-08-20       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.